Strike Three As Novartis’s Ilaris Swings And Misses In Lung Cancer

Anti-Inflammatory Drug Fails In A Third Setting

 
• By Mandy Jackson
Target shot opportunity dartboard performance
The third Phase III miss for Ilaris in NSCLC is in the adjuvant setting • Source: Shutterstock

More from Clinical Trials

More from R&D